Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

达帕格列嗪 医学 危险系数 心力衰竭 心肌梗塞 内科学 安慰剂 心脏病学 心房颤动 糖尿病 置信区间 2型糖尿病 内分泌学 替代医学 病理
作者
Stefan James,David Erlinge,Robert F. Storey,Darren K. McGuire,Mark de Belder,Niclas Eriksson,Kasper Andersen,David Austin,Gabriel Arefalk,David Carrick,Robin Hofmann,Stephen P. Hoole,Daniel A. Jones,Kelvin Lee,Hans Tygesen,Peter A. Johansson,Anna Maria Langkilde,Wilhelm Ridderstråle,Ehsan Parvaresh Rizi,John Deanfield,Jonas Oldgren
出处
期刊:NEJM evidence [New England Journal of Medicine]
卷期号:3 (2) 被引量:105
标识
DOI:10.1056/evidoa2300286
摘要

BACKGROUND: In patients with acute myocardial infarction (MI), therapies that could further reduce the risk of adverse cardiovascular and metabolic outcomes are needed. METHODS: In this international registry-based, randomized, double-blind trial, patients without prior diabetes or chronic heart failure, presenting with acute MI and impaired left ventricular systolic function, were randomly assigned 10 mg of dapagliflozin or placebo, given once daily. The primary outcome was the hierarchical composite of death, hospitalization for heart failure, nonfatal MI, atrial fibrillation/flutter, type 2 diabetes mellitus, New York Heart Association Functional Classification at the last visit, and body weight decrease of 5% or greater at the last visit using the win ratio analysis method. The key secondary outcome was the same hierarchical composite excluding the body weight component. RESULTS: We enrolled 4017 patients of whom 2019 were assigned to dapagliflozin and 1998 to placebo. The analysis of the primary hierarchical composite outcome resulted in significantly more wins for dapagliflozin than for placebo (win ratio, 1.34; 95% confidence interval [CI], 1.20 to 1.50; P<0.001). The win ratio outcome, which was adopted in a change of analysis during trial performance because of low event accrual, was mainly driven by the added cardiometabolic outcomes. The composite of time to cardiovascular death/hospitalization for heart failure occurred in 50/2019 (2.5%) patients assigned to dapagliflozin and 52/1998 (2.6%) patients assigned to placebo (hazard ratio, 0.95; 95% CI, 0.64 to 1.40). The rates of other cardiovascular events were low, with differences between the groups not reaching nominal statistical significance. No safety concerns were identified. CONCLUSIONS: In patients with acute MI as noted above, after approximately 1 year of treatment with dapagliflozin there were significant benefits with regard to improvement in cardiometabolic outcomes but no impact on the composite of cardiovascular death or hospitalization for heart failure compared with placebo. (Funded by AstraZeneca; ClinicalTrial.gov number, NCT04564742.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XZY发布了新的文献求助10
刚刚
烟花应助roxy采纳,获得10
刚刚
热心市民小红花应助昵称采纳,获得10
1秒前
星辰大海应助fei采纳,获得10
1秒前
1秒前
顾越完成签到,获得积分10
2秒前
乐乐应助daxiong采纳,获得10
3秒前
pazhao发布了新的文献求助10
3秒前
10秒前
坦率的正豪完成签到,获得积分10
10秒前
酷波er应助甜美不评采纳,获得10
11秒前
12秒前
12秒前
木木发布了新的文献求助10
13秒前
Emily发布了新的文献求助10
13秒前
共行完成签到 ,获得积分10
13秒前
13秒前
顾矜应助科研通管家采纳,获得10
14秒前
FashionBoy应助科研通管家采纳,获得10
14秒前
ll应助科研通管家采纳,获得10
14秒前
科研通AI5应助科研通管家采纳,获得10
14秒前
ding应助科研通管家采纳,获得10
14秒前
汉堡包应助科研通管家采纳,获得10
14秒前
ll应助科研通管家采纳,获得10
15秒前
ll应助科研通管家采纳,获得10
15秒前
充电宝应助科研通管家采纳,获得10
15秒前
大模型应助科研通管家采纳,获得10
15秒前
星辰大海应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
15秒前
16秒前
15858833895发布了新的文献求助10
17秒前
17秒前
在水一方应助影子采纳,获得10
17秒前
默默问晴完成签到,获得积分10
17秒前
zly发布了新的文献求助10
18秒前
18秒前
JamesPei应助忧虑的代芙采纳,获得10
18秒前
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975610
求助须知:如何正确求助?哪些是违规求助? 3519986
关于积分的说明 11200337
捐赠科研通 3256337
什么是DOI,文献DOI怎么找? 1798246
邀请新用户注册赠送积分活动 877446
科研通“疑难数据库(出版商)”最低求助积分说明 806357